Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL Meeting Abstract
| Authors: | Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; Owens, C. N.; Palomba, M. L.; Kumar, A.; Roeker, L. E.; Thompson, M.; Takvorian, R. W.; Epstein‐Peterson, Z.; Geyer, M.; Ramos‐Amador, W.; Mahajan, N.; Martignetti, R.; Plummer, S. F.; Mi, J.; Lynch, J. M.; McGree, B. M.; Sherburne, M. M.; Patterson, E. N.; Slupe, N.; Chabowska, M.; Labarre, A.; Choma, M.; McCambridge, G.; Kelly, H.; Devlin, M. C.; Puccio, M. G.; Garcia, R. N.; Grieve, C.; Cohen, A.; Blondo, J.; Jacob, A.; Abdel-Wahab, O.; Zelenetz, A. D. |
| Abstract Title: | Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL |
| Meeting Title: | 17th International Conference on Malignant Lymphoma (ICML) |
| Journal Title: | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Jun 13-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 233 |
| End Page: | 235 |
| Language: | English |
| DOI: | 10.1002/hon.3163_153 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 153 -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
